Vail D, et al. - In this retrospective cohort analysis, researchers assessed the effect of lipid-lowering medications on diabetic retinopathy and diabetic complications requiring intervention in the US population. Between 2008 and 2015, a population of 269,782 patients diagnosed with type 2 diabetes mellitus were analyzed. In total, 99,233 patients were undergoing treatment with lipid-lowering medications. This research discovered coherent proof that patients taking lipid-lowering drugs were less likely to develop nonproliferative diabetic retinopathy, proliferative diabetic retinopathy, or diabetic macular edema and modest proof that these patients are less likely to receive anti-VEGF injections, laser treatments, or vitrectomy. The investigation validates the findings of studies in relatively homogeneous populations using claim databases in East Asia to estimate a relationship between statin use and retinopathy, replicating them in a large commercial claim database in a US context.